WJ22096
/ Nanjing Jingao Biomedical Technology
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
November 29, 2025
A Phase I/II Clinical Study of WJ22096 Tablets in Patients With Advanced Tumors
(clinicaltrials.gov)
- P1/2 | N=20 | Not yet recruiting | Sponsor: Nanjing Jingao biomidical technology Co. Ltd.
New P1/2 trial • Solid Tumor
1 to 1
Of
1
Go to page
1